AlphAIalphai — Financial news for AI agents
SEC EDGAR 8-KAUG 56 min read$NSLR

Neostellar Capital Corp. (NSLR): Results of Operations and Financial Condition

Neostellar Capital Corp. (NSLR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex99-1.htm EX-99.1 Exhibit 99.1 Neostellar Capital Corp. Reports Second Quarter 2026 Financial Results An Affiliate of Magnetar Invested $20.0 Million in Neostellar Through a Redeemable Promissory Note Subsequent to Quarter-End Net Asset Value of $13.44 Per Share as of

Original reporting
SEC EDGAR 8-K
Published Aug 5, 2026, 8:07 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 7, 2026, 5:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
alphai market briefEarnings
Primary signal
$NSLR
Neutral
medium confidence
Mentioned
$NSLR
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$NSLRNeutralMed
01

Why it matters

Traders can update valuation models using the reported NAV/share and portfolio composition changes, especially the funded TensorWave investment tied to a $350 million Series B and the ClickHouse investment.

02

Market read

The most tradable elements are the reported NAV/share level and the concrete AI compute and data-infrastructure portfolio actions completed during Q2 and shortly after quarter-end.

03

What to watch

The filing emphasizes externally managed transition and SPV structures; investors may need to focus on fee economics and future liquidity/exit timing, not just NAV/share.

Relevance 7/10Novelty 6/10Timing: after-hours filing on Aug 5, 2026

Background

This is an SEC Form 8-K (Item 2.02) with Q2 2026 results and portfolio activity for Neostellar Capital Corp., including NAV/share and investment funding/exits.

Company-level read

Ticker impact

$NSLRNeutralMedium confidence
Context

Neostellar Capital reported Q2 2026 net assets of about $355.9 million, or $13.44 per share, and detailed new investments via Magnetar SPVs.

Expected impact

Likely modest, with focus on NAV/share trajectory and the market’s read-through on the new AI compute and data-infrastructure exposures.

Evidence & confidence

The 8-K provides primary NAV/share figures and specific investment funding/exits, but it is not a guidance change or a market-moving corporate action like a buyback or capital raise.

Market effects

Sector

Adds incremental read-through to private-market exposure in AI compute and data infrastructure, but does not directly change public-sector fundamentals.

Regional

Primarily US-listed closed-end/BDC-style capital markets sentiment.

Global

Limited, as the disclosures are company-specific portfolio and NAV updates.

Counterpoint

What could challenge this read

Lower NAV/share could reflect mark-to-market volatility rather than deterioration, so the new TensorWave and ClickHouse positions may be undervalued by the market.

Key entities

  • issuer
    Neostellar Capital Corp.

    Reports Q2 2026 financial results, NAV/share, and portfolio investment activity.

  • transaction_partner
    Magnetar Invested $20.0 million via redeemable promissory note

    Describes Magnetar’s affiliate investment into Neostellar through a redeemable promissory note.

  • portfolio_company
    TensorWave, Inc.

    Neostellar funded remaining $15 million of a $20 million commitment via a Magnetar SPV tied to TensorWave’s $350 million Series B.

  • portfolio_company
    ClickHouse, Inc.

    Neostellar completed an approximately $9.5 million investment during Q2 2026.

Read at source← All news

Related articles

AUG 11
$JNJMed

Johnson & Johnson vs. Medtronic: Which Healthcare Stock Is Better Positioned After Earnings?

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales of $25.31B (+6.6% YoY) and adjusted EPS of $2.90, both above estimates, and raised full-year guidance to a $101.1B midpoint and $11.68 adjusted EPS. Medtronic (MDT) posted its fastest annual revenue growth in a decade, with FY26 revenue $36.4B and adjusted revenue $36.3B. Article compares post-earnings positioning and risks.

insidermonkey.com4 min
AUG 11
$USNAMedAI 8/10

USANA Health Sciences Q2 Earnings Call Highlights

USANA Health Sciences (NYSE:USNA) reported Q2 updates including a $29 million preliminary non-cash goodwill impairment tied to its Hiya reporting unit and $9 million income tax expense on a $19 million pre-tax loss. Management cited about $30 million to $40 million top-line pressure and $4 million to $5 million margin pressure, plus a Rise packaging disruption. USANA ended with $169 million cash and no debt.

yahoo.com6 min
AUG 11
$NHIMed

National Health Investors: Q2 Earnings Snapshot

National Health Investors Inc. (NHI) reported Q2 funds from operations of $57.8 million, or $1.19 per share, and net income of $55.6 million, or $1.15 per share, with revenue of $121.3 million. The REIT expects full-year funds from operations of $4.74 to $4.79 per share, according to the company.

local3news.com3 min
AUG 11
$SGRYMed

Surgery Partners: Q2 Earnings Snapshot

Surgery Partners Inc. (SGRY) reported a Q2 loss of $15 million, or 12 cents per share. Adjusted earnings were 10 cents per share, and revenue was $848.9 million. The company expects full-year revenue of $3.35 billion to $3.45 billion, according to its earnings release.

local3news.com2 min